ProQR Therapeutics N.V. - Ordinary Shares - Nakit Akışı (NASDAQ:PRQR)

Financials

İşletme faaliyetlerinden elde edilen nakit —————— — Yatırım faaliyetlerinden elde edilen nakit —————— — Finansman faaliyetlerinden elde edilen nakit —————— — Serbest nakit akışı —————— —

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.

PRQR

Financials

ProQR Therapeutics N.V. - Ordinary Shares

Haberler

Citizens, ProQR hissesi için hedef fiyatı korudu

ProQR Therapeutics N.V. (PRQR) Presents at TIDES USA 2026 - Slideshow (NASDAQ:PRQR) 2026-05-15

Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates

Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

ProQR, Boehringer Ingelheim yöneticisini yönetim kuruluna aday gösterdi

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

ProQR RNA düzenleme hattını güncelledi, biliyer atreziyi hedefliyor

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-04-08

ProQR, yapay zeka ilaç keşfi için Ginkgo ile ortaklık kurdu

ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript

Citizens, ProQR Therapeutics hissesi için hedefini yineledi